Daonil to be discontinued in Australia 3 July 2026 People living with type 2 diabetes who use Daonil are encouraged to speak with their doctor or diabetes healthcare team following confirmation that the medicine will be discontinued in Australia. The Therapeutic Goods Administration (TGA) has advised that Daonil (glibenclamide) 5 mg tablets will be permanently withdrawn from the Australian market from 30 November 2026. The sponsor, Sanofi-Aventis Australia, said that the discontinuation is due to commercial viability considerations. Daonil is a sulfonylurea medicine used to treat type 2 diabetes. While it remains an effective treatment option for some people, prescribing has declined over time with the introduction of newer medicines, including SGLT2 inhibitors, DPP-4 inhibitors and GLP-1 receptor agonists. Anyone currently taking Daonil should make an appointment with their doctor or diabetes healthcare team well before November 2026 to discuss suitable alternative treatment options based on their individual circumstances. Other sulfonylurea medicines, including gliclazide, glimepiride and glipizide, remain available in Australia.
News 30 June 2026 PBS listing of Tresiba Penfill good news for people living with type 1 diabetes Diabetes Australia has welcomed the Australian Government’s decision to list Tresiba Penfill (insulin degludec) on the Pharmaceutical Benefits Scheme (PBS) for people... Continue Reading
Blog 29 June 2026 Winter walks are a simple path to better wellbeing Staying active through the colder months is one of the best things you can do for your health. And what better way to move your body than a good bushwalk? Continue Reading
News 19 June 2026 Diabetes Australia strengthens lived experience voices with revised Constitution Everything Diabetes Australia does – every investment, every policy, every service – is to support our diabetes community. Today, Diabetes... Continue Reading